Other Events ·
Clinuvel Pharmaceuticals Limited announced the completion of development for ZEROKIN™, a proprietary single-use…
CUVLClinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited announced the completion of development for ZEROKIN™, a proprietary single-use subcutaneous administration device designed for controlled-release formulations. The company has submitted an intellectual property application and plans to appoint a commercial manufacturer while preparing a Class II FDA 510(k) dossier and CE marking application. This initiative supports Clinuvel's pipeline of melanocortin peptides, including afamelanotide, by enabling versatile delivery options for hospital and self-administration use. Clinuvel is a global biopharmaceutical company focused on developing innovative therapies for genetic, metabolic, and dermatological disorders.